366 related articles for article (PubMed ID: 32289501)
41. Secretor Status is Associated with Susceptibility to Disease in a Large GII.6 Norovirus Foodborne Outbreak.
Sharma S; Hagbom M; Carlsson B; Nederby Öhd J; Insulander M; Eriksson R; Simonsson M; Widerström M; Nordgren J
Food Environ Virol; 2020 Mar; 12(1):28-34. PubMed ID: 31664650
[TBL] [Abstract][Full Text] [Related]
42. Genomic and biological characterization of a pandemic norovirus variant GII.4 Sydney 2012.
Ge L; Chen X; Liu J; Zheng L; Chen C; Luo S; Guo P; Kong J; Song Y; Huo Y
Virus Genes; 2020 Apr; 56(2):174-181. PubMed ID: 31912284
[TBL] [Abstract][Full Text] [Related]
43. Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity.
Debbink K; Lindesmith LC; Donaldson EF; Costantini V; Beltramello M; Corti D; Swanstrom J; Lanzavecchia A; Vinjé J; Baric RS
J Infect Dis; 2013 Dec; 208(11):1877-87. PubMed ID: 23908476
[TBL] [Abstract][Full Text] [Related]
44. Serological Correlates of Protection against a GII.4 Norovirus.
Atmar RL; Bernstein DI; Lyon GM; Treanor JJ; Al-Ibrahim MS; Graham DY; Vinjé J; Jiang X; Gregoricus N; Frenck RW; Moe CL; Chen WH; Ferreira J; Barrett J; Opekun AR; Estes MK; Borkowski A; Baehner F; Goodwin R; Edmonds A; Mendelman PM
Clin Vaccine Immunol; 2015 Aug; 22(8):923-9. PubMed ID: 26041041
[TBL] [Abstract][Full Text] [Related]
45. Norovirus GII.4 antibodies in breast milk and serum samples: their role preventing virus-like particles binding to their receptors.
Khodayar-Pardo P; Martínez-Costa C; Carmona-Vicente N; Buesa J
Pediatr Infect Dis J; 2014 Jun; 33(6):554-9. PubMed ID: 24830517
[TBL] [Abstract][Full Text] [Related]
46. Herd immunity to GII.4 noroviruses is supported by outbreak patient sera.
Cannon JL; Lindesmith LC; Donaldson EF; Saxe L; Baric RS; Vinjé J
J Virol; 2009 Jun; 83(11):5363-74. PubMed ID: 19297483
[TBL] [Abstract][Full Text] [Related]
47. Increase in genogroup II.4 norovirus host spectrum by CagA-positive Helicobacter pylori infection.
Ruvoën-Clouet N; Magalhaes A; Marcos-Silva L; Breiman A; Figueiredo C; David L; Le Pendu J
J Infect Dis; 2014 Jul; 210(2):183-91. PubMed ID: 24459192
[TBL] [Abstract][Full Text] [Related]
48. Broadly cross-reactive human antibodies that inhibit genogroup I and II noroviruses.
Alvarado G; Salmen W; Ettayebi K; Hu L; Sankaran B; Estes MK; Venkataram Prasad BV; Crowe JE
Nat Commun; 2021 Jul; 12(1):4320. PubMed ID: 34262046
[TBL] [Abstract][Full Text] [Related]
49. Human norovirus inhibition by a human milk oligosaccharide.
Koromyslova A; Tripathi S; Morozov V; Schroten H; Hansman GS
Virology; 2017 Aug; 508():81-89. PubMed ID: 28505592
[TBL] [Abstract][Full Text] [Related]
50. Characterization of Antigenic Relatedness between GII.4 and GII.17 Noroviruses by Use of Serum Samples from Norovirus-Infected Patients.
Dai YC; Xia M; Huang Q; Tan M; Qin L; Zhuang YL; Long Y; Li JD; Jiang X; Zhang XF
J Clin Microbiol; 2017 Dec; 55(12):3366-3373. PubMed ID: 28904188
[TBL] [Abstract][Full Text] [Related]
51. Human Norovirus Neutralized by a Monoclonal Antibody Targeting the Histo-Blood Group Antigen Pocket.
Koromyslova AD; Morozov VA; Hefele L; Hansman GS
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541855
[TBL] [Abstract][Full Text] [Related]
52. Pathogenesis and immune responses in gnotobiotic calves after infection with the genogroup II.4-HS66 strain of human norovirus.
Souza M; Azevedo MS; Jung K; Cheetham S; Saif LJ
J Virol; 2008 Feb; 82(4):1777-86. PubMed ID: 18045944
[TBL] [Abstract][Full Text] [Related]
53. Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002.
Lindesmith LC; Debbink K; Swanstrom J; Vinjé J; Costantini V; Baric RS; Donaldson EF
J Virol; 2012 Jan; 86(2):873-83. PubMed ID: 22090098
[TBL] [Abstract][Full Text] [Related]
54. Human Norovirus Epitope D Plasticity Allows Escape from Antibody Immunity without Loss of Capacity for Binding Cellular Ligands.
Lindesmith LC; Brewer-Jensen PD; Mallory ML; Yount B; Collins MH; Debbink K; Graham RL; Baric RS
J Virol; 2019 Jan; 93(2):. PubMed ID: 30355694
[TBL] [Abstract][Full Text] [Related]
55. Within-host evolution of virus variants during chronic infection with novel GII.P26-GII.26 norovirus.
Pietsch C; Ennuschat N; Härtel S; Liebert UG
J Clin Virol; 2018 Nov; 108():96-102. PubMed ID: 30268000
[TBL] [Abstract][Full Text] [Related]
56. Qualitative and quantitative analysis of the binding of GII.4 norovirus variants onto human blood group antigens.
de Rougemont A; Ruvoen-Clouet N; Simon B; Estienney M; Elie-Caille C; Aho S; Pothier P; Le Pendu J; Boireau W; Belliot G
J Virol; 2011 May; 85(9):4057-70. PubMed ID: 21345963
[TBL] [Abstract][Full Text] [Related]
57. [Interaction between noroviruses and human histo-blood group antigens].
Shirato-Horikoshi H; Takeda N
Uirusu; 2007 Dec; 57(2):181-9. PubMed ID: 18357756
[TBL] [Abstract][Full Text] [Related]
58. Genetic susceptibility to norovirus GII.3 and GII.4 infections in Chinese pediatric diarrheal disease.
Liu P; Wang X; Lee JC; Teunis P; Hu S; Paradise HT; Moe C
Pediatr Infect Dis J; 2014 Nov; 33(11):e305-9. PubMed ID: 25037042
[TBL] [Abstract][Full Text] [Related]
59. Epidemiologic, Virologic, and Host Genetic Factors of Norovirus Outbreaks in Long-term Care Facilities.
Costantini VP; Cooper EM; Hardaker HL; Lee LE; Bierhoff M; Biggs C; Cieslak PR; Hall AJ; Vinjé J
Clin Infect Dis; 2016 Jan; 62(1):1-10. PubMed ID: 26508509
[TBL] [Abstract][Full Text] [Related]
60. Within-host evolution results in antigenically distinct GII.4 noroviruses.
Debbink K; Lindesmith LC; Ferris MT; Swanstrom J; Beltramello M; Corti D; Lanzavecchia A; Baric RS
J Virol; 2014 Jul; 88(13):7244-55. PubMed ID: 24648459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
